FortuneTrace
Serenity
Serenity (@aleabitoreddit)Serenity@aleabitoredditPost2026-08-06

Viavi CEO refutes CPO delay rumors, states CPO testing revenue is already hitting this qua

Viavi CEO refutes CPO delay rumors, states CPO testing revenue is already hitting this quarter and will accelerate in December. The company has purchase orders for CPO testing activity. Also notes 1.6T ramping quickly, expected to reach parity with 800G next year. The post suggests CPO test revenues are now flowing to VIAV and FORM.

Funniest callout of the year from $VIAV on CPO timelines: "Well, there's been a lot of industry talk [about delays], like, 'Oh, because the yield is going to be slower.' That's all nonsense. CPO and all that thing is moving forward" They stated that Yes there's always issues, but the process is being improved and things are getting better. To follow up on that, the CEO stated: - Viavi has POs for CPO-testing activity - “We’re already getting [CPO revenue] this quarter, and probably in December it will start accelerating.” On a side note, they also stated, 1.6T is "ramping very quickly", should reach parity with 800g next year, and signaled longer tail for 800g demand. TLDR: Seeing CPO test revenues hit for $VIAV to $FORM around now. Nvidia also stated switch-side CPO for scale out and scale across has entered mass production earlier. As for scale up timelines, early production should be H2 2027 for some players, with other CPO players Ayar stating 2028 is the volume inflection period. Basically, all the timelines seem to be the same as before and revenue is starting to hit testing players first.
Original postX / @aleabitoreddit

Related stocks

VIAVBullish
-3.52% today
-26.60% 90d

CEO confirmed CPO testing revenue already this quarter with POs in hand, and acceleration expected in December, contradicting industry delay rumors.

Trade
FORMBullish
-4.87% today
-23.26% 90d

Also mentioned in context of CPO testing revenue starting to hit, implying involvement in CPO test equipment.

Trade
Information only · SignalTrace is an information tool, not investment advice. It does not recommend buying or selling any security. Schedules may be based on media reports before official confirmation. Survivorship bias applies to public track records. You are responsible for your own decisions.